Abstract
Purpose: The development of “small-for-size” syndrome (SFSS) after extended hepatectomies is associated with dreadful consequences for the patient. Excessive portal pressure and flow in the remnant liver may cause severe endothelial injury and impairs the normal process of liver regeneration leading to postoperative liver insufficiency. Somatostatin has been described as a protective pharmacological agent to prevent this syndrome when a partial graft is transplanted for its hemodynamic effects in the splanchnic area.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
